Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising questions on their potential immunogenicity and effects on treatment. In this review, we ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Davda, Jasmine, Declerck, Paul, Hu-Lieskovan, Siwen, Hickling, Timothy P., Jacobs, Ira A., Chou, Jeffrey, Salek-Ardakani, Shahram, Kraynov, Eugenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466770/
https://www.ncbi.nlm.nih.gov/pubmed/30992085
http://dx.doi.org/10.1186/s40425-019-0586-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466770/
https://www.ncbi.nlm.nih.gov/pubmed/30992085
http://dx.doi.org/10.1186/s40425-019-0586-0

Ejemplares similares